LAUSR

About LAUSR
Donate
Contact Us

Follow us:

You are not signed in:

Sign Up!


   Articles with "axi" as a keyword



Photo from wikipedia

First-line Treatment of Metastatic Renal Cell Carcinoma in the Immuno-oncology Era: Systematic Review and Network Meta-analysis.

Sign Up to like & get
recommendations! Published in 2020 at "Clinical genitourinary cancer"

DOI: 10.1016/j.clgc.2020.02.012

Abstract: Combination treatments with immuno-oncology (IO) agents and IO agents plus a vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI) have been approved for first-line treatment of patients with metastatic renal cell carcinoma (mRCC). No… read more here.

Keywords: pembro axi; first line; line treatment; oncology ... See more keywords
Photo by taylor65s from unsplash

Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed/refractory follicular lymphoma

Sign Up to like & get
recommendations! Published in 2022 at "Blood"

DOI: 10.1182/blood.2021014375

Abstract: As yet, there are no randomized studies of chimeric antigen receptor (CAR) T-cell therapy versus standard therapy in patients with multiple relapsed follicular lymphoma. To provide early insight into comparative efficacy, Ghione et al used… read more here.

Keywords: axi; follicular lymphoma; axi cel; zuma ... See more keywords
Photo from wikipedia

Phase I/II study of axitinib (axi) and nivolumab (nivo) in patients with metastatic renal cell carcinoma (mRCC).

Sign Up to like & get
recommendations! Published in 2019 at "Journal of Clinical Oncology"

DOI: 10.1200/jco.2019.37.15_suppl.4567

Abstract: 4567 Background: Drug combinations targeting vascular endothelial growth factor (VEGF) and the programmed death one (PD-1) pathway have demonstrated encouraging efficacy in patients (pts) with mRCC. We are conducting a phase I/II trial combining the… read more here.

Keywords: axi; trial; efficacy; mrcc ... See more keywords
Photo by maxime_dore from unsplash

Angiogenic and immunomodulatory biomarkers in axitinib-treated patients (pts) with advanced renal cell carcinoma (aRCC).

Sign Up to like & get
recommendations! Published in 2019 at "Journal of Clinical Oncology"

DOI: 10.1200/jco.2019.37.7_suppl.614

Abstract: 614 Background: Axitinib (axi) is approved for 2nd-line treatment of aRCC. In AXIS trial, median progression-free survival (PFS) was significantly longer in axi- vs sorafenib (sor)-treated pts (hazard ratio [HR] 0.67, 95% CI 0.54–0.81, P read more here.

Keywords: axi sor; axi; treated pts; angiogenic immunomodulatory ... See more keywords